The 340B Drug Pricing Program was originally constructed so safety-net health care facilities could stretch scarce resources in caring for low-income patients. However, the program has experienced ...

Lawmakers impatient with the lack of progress on a key health care issue — the long-debated need for changes to what’s known as the 340B drug pricing program — say they are closing in on legislation ...

The Trump administration has approved eight drugmakers' rebate plans for a controversial 340B drug discount pilot program that kicks off Jan. 1. The 340B Rebate Model Pilot Program, unveiled this ...

Dan Crippen was the director of the Congressional Budget Office from 1999 to 2003. In its first report on the 340B drug discount program's effect on the budget, the Congressional Budget Office ...

The American Society of Health-System Pharmacists is urging lawmakers to protect the 340B Drug Pricing Program, warning that changes to the discount model could destabilize safety-net hospitals. In an ...

Every Illinoisan deserves access to affordable quality health care close to home, including medication. That’s why I fully support legislation in Springfield that protects the federal 340B drug ...

WASHINGTON — Lawmakers impatient with the lack of progress on a key health care issue — the long-debated need for changes to what’s known as the 340B drug pricing program — say they are closing in on ...

Even as they sparred on broader healthcare policy and funding topics fueling the ongoing government shutdown, senators of the Health, Education, Labor and Pensions Committee appear to agree that ...

As the Trump administration prepares to force its Most Favored Nation price controls on drug makers, a major U.S. lobbying group is pushing for a change to drug discounts law that would necessitate a ...

Throughout the country, the health care system is changing. Those effects can be felt in Western New York. Costs are increasing and independent practices are disappearing. A major driver of those ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...